Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population.

Wilson TR, Yu J, Lu X, Spoerke JM, Xiao Y, O'Brien C, Savage HM, Huw LY, Zou W, Koeppen H, Forrest WF, Fridlyand J, Fu L, Tam R, Schleifman EB, Sumiyoshi T, Molinero L, Hampton GM, O'Shaughnessy JA, Lackner MR.

NPJ Breast Cancer. 2016 Jul 13;2:16022. doi: 10.1038/npjbcancer.2016.22. eCollection 2016.

2.

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples.

Wilson TR, Xiao Y, Spoerke JM, Fridlyand J, Koeppen H, Fuentes E, Huw LY, Abbas I, Gower A, Schleifman EB, Desai R, Fu L, Sumiyoshi T, O'Shaughnessy JA, Hampton GM, Lackner MR.

Breast Cancer Res Treat. 2014 Nov;148(2):315-25. doi: 10.1007/s10549-014-3163-8. Epub 2014 Oct 22.

3.

Considerations for the successful co-development of targeted cancer therapies and companion diagnostics.

Fridlyand J, Simon RM, Walrath JC, Roach N, Buller R, Schenkein DP, Flaherty KT, Allen JD, Sigal EV, Scher HI.

Nat Rev Drug Discov. 2013 Oct;12(10):743-55. doi: 10.1038/nrd4101. Epub 2013 Sep 6. Review.

PMID:
24008432
4.

An industry statistician's perspective on PHC drug development.

Fridlyand J, Yeh RF, Mackey H, Bengtsson T, Delmar P, Spaniolo G, Lieberman G.

Contemp Clin Trials. 2013 Nov;36(2):624-35. doi: 10.1016/j.cct.2013.04.006. Epub 2013 May 3. Review.

PMID:
23648396
5.

Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.

Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, Haverty PM, Pandita A, Mohan S, Sampath D, Friedman LS, Ross L, Hampton GM, Amler LC, Shames DS, Lackner MR.

Clin Cancer Res. 2012 Dec 15;18(24):6771-83. doi: 10.1158/1078-0432.CCR-12-2347. Epub 2012 Nov 7.

6.

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J.

Nature. 2012 Jul 26;487(7408):505-9. doi: 10.1038/nature11249.

7.

Analysis of tumor burden versus progression-free survival for Phase II decision making.

Fridlyand J, Kaiser LD, Fyfe G.

Contemp Clin Trials. 2011 May;32(3):446-52. doi: 10.1016/j.cct.2011.01.010. Epub 2011 Jan 23.

PMID:
21266203
8.

Statistical techniques to construct assays for identifying likely responders to a treatment under evaluation from cell line genomic data.

Huang EP, Fridlyand J, Lewin-Koh N, Yue P, Shi X, Dornan D, Burington B.

BMC Cancer. 2010 Oct 27;10:586. doi: 10.1186/1471-2407-10-586.

9.

Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma.

Costa BM, Smith JS, Chen Y, Chen J, Phillips HS, Aldape KD, Zardo G, Nigro J, James CD, Fridlyand J, Reis RM, Costello JF.

Cancer Res. 2010 Jan 15;70(2):453-62. doi: 10.1158/0008-5472.CAN-09-2189. Epub 2010 Jan 12.

10.

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.

Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB.

Cancer Res. 2009 May 15;69(10):4116-24. doi: 10.1158/0008-5472.CAN-08-3441. Epub 2009 May 12.

11.

Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis.

Kwek SS, Roy R, Zhou H, Climent J, Martinez-Climent JA, Fridlyand J, Albertson DG.

Oncogene. 2009 Apr 30;28(17):1892-903. doi: 10.1038/onc.2009.34. Epub 2009 Mar 30.

12.

Improving melanoma classification by integrating genetic and morphologic features.

Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D, Bastian BC.

PLoS Med. 2008 Jun 3;5(6):e120. doi: 10.1371/journal.pmed.0050120.

13.

High-resolution genomic and expression analyses of copy number alterations in breast tumors.

Haverty PM, Fridlyand J, Li L, Getz G, Beroukhim R, Lohr S, Wu TD, Cavet G, Zhang Z, Chant J.

Genes Chromosomes Cancer. 2008 Jun;47(6):530-42. doi: 10.1002/gcc.20558.

PMID:
18335499
14.

Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer.

Lee SA, Ho C, Roy R, Kosinski C, Patil MA, Tward AD, Fridlyand J, Chen X.

Hepatology. 2008 Apr;47(4):1200-10. doi: 10.1002/hep.22169.

PMID:
18214995
15.

Protein biomarker identification in the CSF of patients with CNS lymphoma.

Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL.

J Clin Oncol. 2008 Jan 1;26(1):96-105. Epub 2007 Dec 3.

16.

Evaluation of whole genome amplification protocols for array and oligonucleotide CGH.

Hittelman A, Sridharan S, Roy R, Fridlyand J, Loda M, Collins C, Paris PL.

Diagn Mol Pathol. 2007 Dec;16(4):198-206.

PMID:
18043282
17.

Acquired genomic aberrations associated with methotrexate resistance vary with background genomic instability.

Snijders AM, Hermsen MA, Baughman J, Buffart TE, Huey B, Gajduskova P, Roydasgupta R, Tokuyasu T, Meijer GA, Fridlyand J, Albertson DG.

Genes Chromosomes Cancer. 2008 Jan;47(1):71-83.

PMID:
17943968
18.

Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer.

Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, Kalloger SE, Carlson JW, Ginzinger DG, Celniker SE, Mills GB, Huntsman DG, Gray JW.

Clin Cancer Res. 2007 Oct 1;13(19):5745-55.

19.

Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers.

Yau C, Fedele V, Roydasgupta R, Fridlyand J, Hubbard A, Gray JW, Chew K, Dairkee SH, Moore DH, Schittulli F, Tommasi S, Paradiso A, Albertson DG, Benz CC.

Breast Cancer Res. 2007;9(5):R59.

20.

Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.

Tomioka N, Oba S, Ohira M, Misra A, Fridlyand J, Ishii S, Nakamura Y, Isogai E, Hirata T, Yoshida Y, Todo S, Kaneko Y, Albertson DG, Pinkel D, Feuerstein BG, Nakagawara A.

Oncogene. 2008 Jan 17;27(4):441-9. Epub 2007 Jul 16.

PMID:
17637744
21.

FBXW7 and DNA copy number instability.

Byrd KN, Huey B, Roydasgupta R, Fridlyand J, Snijders AM, Albertson DG.

Breast Cancer Res Treat. 2008 May;109(1):47-54. Epub 2007 Jun 23.

PMID:
17588203
22.

Genome position and gene amplification.

Gajduskova P, Snijders AM, Kwek S, Roydasgupta R, Fridlyand J, Tokuyasu T, Pinkel D, Albertson DG.

Genome Biol. 2007;8(6):R120.

23.

Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.

Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, O'Brien J, Haqq C, Shuman M.

J Clin Oncol. 2007 Apr 10;25(11):1350-6. Epub 2007 Feb 20.

PMID:
17312328
24.

Lack of germ-line promoter methylation in BRCA1-negative families with familial breast cancer.

Chen Y, Toland AE, McLennan J, Fridlyand J, Crawford B, Costello JF, Ziegler JL.

Genet Test. 2006 Winter;10(4):281-4.

PMID:
17253935
25.

Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer.

Climent J, Dimitrow P, Fridlyand J, Palacios J, Siebert R, Albertson DG, Gray JW, Pinkel D, Lluch A, Martinez-Climent JA.

Cancer Res. 2007 Jan 15;67(2):818-26.

26.

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.

Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW.

Cancer Cell. 2006 Dec;10(6):529-41.

27.

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW.

Cancer Cell. 2006 Dec;10(6):515-27.

28.

Chromosomal instability in microsatellite-unstable and stable colon cancer.

Trautmann K, Terdiman JP, French AJ, Roydasgupta R, Sein N, Kakar S, Fridlyand J, Snijders AM, Albertson DG, Thibodeau SN, Waldman FM.

Clin Cancer Res. 2006 Nov 1;12(21):6379-85.

29.

Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: A matrix-based CGH approach.

Thorns C, Bastian B, Pinkel D, Roydasgupta R, Fridlyand J, Merz H, Krokowski M, Bernd HW, Feller AC.

Genes Chromosomes Cancer. 2007 Jan;46(1):37-44.

PMID:
17044049
30.

Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells.

Reynolds PA, Sigaroudinia M, Zardo G, Wilson MB, Benton GM, Miller CJ, Hong C, Fridlyand J, Costello JF, Tlsty TD.

J Biol Chem. 2006 Aug 25;281(34):24790-802. Epub 2006 Jun 9.

31.

Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel.

Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, Kuo WL, Gwadry F, Ajay, Kouros-Mehr H, Fridlyand J, Jain A, Collins C, Nishizuka S, Tonon G, Roschke A, Gehlhaus K, Kirsch I, Scudiero DA, Gray JW, Weinstein JN.

Mol Cancer Ther. 2006 Apr;5(4):853-67.

32.

Breast tumor copy number aberration phenotypes and genomic instability.

Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, Dairkee S, Tokuyasu T, Ljung BM, Jain AN, McLennan J, Ziegler J, Chin K, Devries S, Feiler H, Gray JW, Waldman F, Pinkel D, Albertson DG.

BMC Cancer. 2006 Apr 18;6:96.

33.

Genomic analysis of tumors by array comparative genomic hybridization: more is better.

Albertson DG, Snijders AM, Fridlyand J, Jordan R, Pinkel D, Schmidt BL.

Cancer Res. 2006 Apr 1;66(7):3955-6; author reply 3956. No abstract available.

34.

Gene expression and angiotropism in primary CNS lymphoma.

Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, Shuman M.

Blood. 2006 May 1;107(9):3716-23. Epub 2006 Jan 17.

35.

Distinct sets of genetic alterations in melanoma.

Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC.

N Engl J Med. 2005 Nov 17;353(20):2135-47.

36.

Therapy-induced malignant neoplasms in Nf1 mutant mice.

Chao RC, Pyzel U, Fridlyand J, Kuo YM, Teel L, Haaga J, Borowsky A, Horvai A, Kogan SC, Bonifas J, Huey B, Jacks TE, Albertson DG, Shannon KM.

Cancer Cell. 2005 Oct;8(4):337-48.

37.

Bladder cancer stage and outcome by array-based comparative genomic hybridization.

Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, Pejavar S, Mehta K, Carroll P, Simko JP, Waldman FM.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):7012-22.

38.

A comparison study: applying segmentation to array CGH data for downstream analyses.

Willenbrock H, Fridlyand J.

Bioinformatics. 2005 Nov 15;21(22):4084-91. Epub 2005 Sep 13.

PMID:
16159913
39.

Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3.

Ching TT, Maunakea AK, Jun P, Hong C, Zardo G, Pinkel D, Albertson DG, Fridlyand J, Mao JH, Shchors K, Weiss WA, Costello JF.

Nat Genet. 2005 Jun;37(6):645-51. Epub 2005 May 15.

PMID:
15895082
40.

Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma.

Snijders AM, Schmidt BL, Fridlyand J, Dekker N, Pinkel D, Jordan RC, Albertson DG.

Oncogene. 2005 Jun 16;24(26):4232-42.

PMID:
15824737
41.

Mapping segmental and sequence variations among laboratory mice using BAC array CGH.

Snijders AM, Nowak NJ, Huey B, Fridlyand J, Law S, Conroy J, Tokuyasu T, Demir K, Chiu R, Mao JH, Jain AN, Jones SJ, Balmain A, Pinkel D, Albertson DG.

Genome Res. 2005 Feb;15(2):302-11.

42.

Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors.

Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JE, Volik S, Albertson DG, Pinkel D, Alers JC, van der Kwast TH, Vissers KJ, Schroder FH, Wildhagen MF, Febbo PG, Chinnaiyan AM, Pienta KJ, Carroll PR, Rubin MA, Collins C, van Dekken H.

Hum Mol Genet. 2004 Jul 1;13(13):1303-13. Epub 2004 May 11.

PMID:
15138198
43.

Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway.

Maldonado JL, Timmerman L, Fridlyand J, Bastian BC.

Am J Pathol. 2004 May;164(5):1783-7.

44.

Oncogene expression and genetic background influence the frequency of DNA copy number abnormalities in mouse pancreatic islet cell carcinomas.

Hager JH, Hodgson JG, Fridlyand J, Hariono S, Gray JW, Hanahan D.

Cancer Res. 2004 Apr 1;64(7):2406-10.

45.

High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization.

Nakao K, Mehta KR, Fridlyand J, Moore DH, Jain AN, Lafuente A, Wiencke JW, Terdiman JP, Waldman FM.

Carcinogenesis. 2004 Aug;25(8):1345-57. Epub 2004 Mar 4.

PMID:
15001537
46.

Determinants of BRAF mutations in primary melanomas.

Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, Ono T, Albertson DG, Pinkel D, Bastian BC.

J Natl Cancer Inst. 2003 Dec 17;95(24):1878-90.

PMID:
14679157
47.

Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis.

Korkola JE, DeVries S, Fridlyand J, Hwang ES, Estep AL, Chen YY, Chew KL, Dairkee SH, Jensen RM, Waldman FM.

Cancer Res. 2003 Nov 1;63(21):7167-75.

48.

Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors.

Hackett CS, Hodgson JG, Law ME, Fridlyand J, Osoegawa K, de Jong PJ, Nowak NJ, Pinkel D, Albertson DG, Jain A, Jenkins R, Gray JW, Weiss WA.

Cancer Res. 2003 Sep 1;63(17):5266-73.

49.

Shaping of tumor and drug-resistant genomes by instability and selection.

Snijders AM, Fridlyand J, Mans DA, Segraves R, Jain AN, Pinkel D, Albertson DG.

Oncogene. 2003 Jul 10;22(28):4370-9.

PMID:
12853973
50.

Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in fallopian tube carcinoma.

Snijders AM, Nowee ME, Fridlyand J, Piek JM, Dorsman JC, Jain AN, Pinkel D, van Diest PJ, Verheijen RH, Albertson DG.

Oncogene. 2003 Jul 3;22(27):4281-6.

PMID:
12833150

Supplemental Content

Loading ...
Support Center